Revolution of Drug-Eluting Coronary Stents: An Analysis of Market Leaders

*Ashok S. Thakkar,1 Bhargav A. Dave2,3

1. Clinical Research, Meril Life Sciences Pvt., Ltd, Vapi, India
2. Manish Therapy Services, Madison Heights, Texas, USA
3. Department of Physical Therapy, Srinivas University, Mangaluru, Karnataka, India
*Correspondence to drashokthakkar@gmail.com

Disclosure: Ashok S. Thakkar is an employee of Meril Life Science Pvt., Ltd. Bhargav A. Dave has declared no conflicts of interest.
Received: 27.04.16 Accepted: 24.08.16
Citation: EMJ. 2016;4[1]:114-125.

Abstract

Percutaneous coronary intervention with drug-eluting stents (DES) is a well-established and widely-accepted treatment approach in patients with coronary artery disease. Although the underlying principle of DES remains constant for different stents available on the market, certain factors may offer variations with respect to deliverability (ease of placement), efficacy (preventing restenosis), and safety (thrombosis rates). These factors may include the type of drug (sirolimus, everolimus, biolimus, zotarolimus, novolimus, paclitaxel, docetaxel), type of stent platforms (stainless steel, platinum, cobalt-chromium, cobalt-nickel, platinum-chromium), type of polymers (permanent, biodegradable, polymer-free), thickness of stent struts (thick, thin, ultra-thin), type of coating (abluminal, conformal), and type of stent design (open-cell, closed-cell, combination of open-closed cell). In this context, we present a review on characteristic features of several of the most widely used coronary stents worldwide. Furthermore, the advancements of completely biodegradable stents are discussed. In addition, the future directions for the development of creating an ideal or perfect DES are debated.

Download (PDF, 213KB)

Comments are closed.